AveXis, Inc. (AVXS) EPS Estimated At $-1.51

February 15, 2018 - By Stephen Andrade

 AveXis, Inc. (AVXS) EPS Estimated At $ 1.51

Analysts expect AveXis, Inc. (NASDAQ:AVXS) to report $-1.51 EPS on March, 15.They anticipate $0.59 EPS change or 64.13 % from last quarter’s $-0.92 EPS. After having $-1.52 EPS previously, AveXis, Inc.’s analysts see -0.66 % EPS growth. The stock decreased 0.62% or $0.72 during the last trading session, reaching $114.88. About 89,577 shares traded. AveXis, Inc. (NASDAQ:AVXS) has risen 95.85% since February 15, 2017 and is uptrending. It has outperformed by 79.15% the S&P500.

AveXis, Inc. (NASDAQ:AVXS) Ratings Coverage

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Monday, September 19 report. The stock has “Market Perform” rating by Wells Fargo on Friday, July 15. The firm earned “Buy” rating on Friday, October 21 by Bank of America. Jefferies upgraded the stock to “Buy” rating in Friday, August 12 report. Goldman Sachs maintained it with “Buy” rating and $47 target in Friday, May 13 report.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $4.19 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

More recent AveXis, Inc. (NASDAQ:AVXS) news were published by: Marketwatch.com which released: “Gene therapy stocks slammed after scientist reveals safety concerns” on January 30, 2018. Also Globenewswire.com published the news titled: “AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS …” on January 30, 2018. Globenewswire.com‘s news article titled: “AveXis Announces Pricing of Public Offering of Common Stock” with publication date: January 17, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: